Key result
Edoxaban provided a positive net clinical benefit of 1.68 saved events per 100 patients per year compared to anti-platelet drugs in clinical trial populations with atrial fibrillation.
Why the study?
Does edoxaban improve net clinical benefit compared to placebo or antiplatelet therapy in patients with non-valvular atrial fibrillation?
Population
203,394 patients with non-valvular atrial fibrillation pooled from 24 studies
Comparison
Edoxaban 30 mg or 60 mg once daily vs Placebo, aspirin alone, or aspirin plus…
Design
Meta-analysis
Authors
Loading...
Edoxaban confers superior net clinical benefit versus antiplatelets or no therapy in AF; extends RCT data to guide choices in intolerant patients.
Meta-Analysis (n=203,394)
Does edoxaban improve net clinical benefit compared to placebo or antiplatelet therapy in patients with non-valvular atrial fibrillation?
Effect estimate: 1.68 saved events per 100 patients per year
p-value: p=< 0.01
Edoxaban provides superior net clinical benefit for stroke prevention with a favorable bleeding profile compared to placebo, aspirin, or dual antiplatelet therapy in patients with non-valvular atrial fibrillation.
Rasmussen et al. (2015) conducted a meta-analysis in non-valvular atrial fibrillation (n=203,394). Edoxaban vs. placebo, aspirin alone, or aspirin plus clopidogrel was evaluated on net clinical benefit (balancing the reduction in stroke risk vs increased risk of haemorrhage) (1.68 saved events per 100 patients per year, p=< 0.01). Edoxaban provided a positive net clinical benefit of 1.68 saved events per 100 patients per year compared to anti-platelet drugs in clinical trial populations with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: